Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Senju Pharmaceutical Co., Ltd. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 4 distinct examiners and 4 distinct art units, indicating a broad technical footprint within the sector. LANKFORD JR, LEON B is the busiest examiner for the portfolio, currently managing 1 pending office action. With 4 pending office actions total distributed among 4 distinct examiners, the company's prosecution efforts are highly decentralized.
Each of the 4 distinct art units likely represents a different therapeutic or chemical focus within the biotechnology field. Because the busiest examiner, LANKFORD JR, LEON B, only handles 1 pending office action, the applicant must coordinate its responses across four different sets of examiner expectations and art unit standards. This distribution suggests that every pending matter is being treated as a unique technical and administrative challenge. Practitioners must be diligent in tracking the specific requirements of each of the 4 distinct examiners to avoid inconsistent prosecution outcomes. The broad reach across multiple art units indicates that the company is protecting a diverse range of pharmaceutical innovations. Successfully navigating this decentralized environment will require a robust strategy that addresses the specific nuances of each individual case while maintaining the overall integrity of the company's intellectual property portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 70.0% | +31.6% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| MEJIAS, SAMANTHA LEE | 1 | 46.4% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18330510 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | LANKFORD JR, LEON B | 54d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18330510 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | LANKFORD JR, LEON B | 54d |
| 17605869 | EYE DISEASE MARKER | MEJIAS, SAMANTHA LEE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1617 | 1 |
| 1658 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18330510 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS | LANKFORD JR, LEON B | 1657 | §102§103 | Non-Final OA | 54d | Pending | Jun 07, 2023 |
| 17796843 | USE OF POLYETHER COMPOUND | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | — | Pending | Aug 01, 2022 |
| 17610844 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | STEELE, AMBER D | 1658 | §103DP | Final Rejection | 22d | Pending | Nov 12, 2021 |
| 17605869 | EYE DISEASE MARKER | MEJIAS, SAMANTHA LEE | 1618 | §103 | Non-Final OA | — | Pending | Oct 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial